In our previous study, the less calcemic, CYP24A1 resistant 1,25D(OH)2D3 analog, EB1089, did not reduce VCaP xenograft tumor growth in vivo despite cell growth reduction in vitro [27] and efficacy in LNCaP xenograft tumors [13]. The gene discussed is CYP24A1; the disease is neoplasm.